← Back to Search

Anticoagulant

Apixaban for COVID-19 (FREEDOM COVID Trial)

Phase 4
Waitlist Available
Led By Valentin Fuster, MD,PhD
Research Sponsored by Valentin Fuster
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 days after randomization
Awards & highlights

FREEDOM COVID Trial Summary

This study is evaluating whether a drug which blocks the ACE2 receptor may help treat SARS-CoV-2.

Eligible Conditions
  • COVID-19
  • Coronavirus

FREEDOM COVID Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 days after randomization
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days after randomization for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of in-hospital rate of BARC 3 or 5
Time to first event
Secondary outcome measures
Cause of Death
Number of All Death
Number of participants requiring Ventilation
+5 more

Side effects data

From 2018 Phase 4 trial • 557 Patients • NCT01884337
7%
Incision site pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
TOTAL KNEE REPLACEMENT (TKR)
TOTAL HIP REPLACEMENT (THR)

FREEDOM COVID Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: ApixabanExperimental Treatment1 Intervention
Apixaban (5 mg Q12h; 2.5 mg Q12h for patients with at least two of three of age ≥80 years, weight ≤60 kg or serum creatinine ≥1.5 mg/dL)
Group II: Prophylactic EnoxaparinActive Control1 Intervention
Prophylactic enoxaparin (40 mg SC QD; 30 mg SC QD for CrCl <30 mL/min)
Group III: Full Dose EnoxaparinActive Control1 Intervention
Full-dose enoxaparin (1 mg/kg SC Q12h; 1 mg/kg SC QD for CrCl <30 mL/min)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Apixaban
2011
Completed Phase 4
~132290

Find a Location

Who is running the clinical trial?

Valentin FusterLead Sponsor
2 Previous Clinical Trials
4,179 Total Patients Enrolled
Valentin Fuster, MD,PhD4.915 ReviewsPrincipal Investigator - Icahn School of Medicine at Mount Sinai
Medical School - Icahn School of Medicine at Mount Sinai, Doctor of Medicine
The Mount Sinai Hospital, Residency in Internal Medicine
5Patient Review
Dr Goldfinger is extremely comprehensive in his approach.
Anu Lala, MDPrincipal InvestigatorIcahn School of Medicine at Mount Sinai

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
FREEDOM COVID-19 Anticoagulation Strategy
Valentin Fuster 2020. "FREEDOM COVID-19 Anticoagulation Strategy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04512079.
~755 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top